FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
Scott Gottlieb's testimony for the House Energy and Commerce Committee, Subcommittee on Health's hearing on drug compounding.
Drug companies -- at least every one that I've worked with -- would like to develop important new medicines that improve health and save lives. That's what gets every industry researcher I know up in the morning, and what keeps them going through the many highs and lows that characterize the scientific process.
Given the tremendous headwinds facing the biopharmaceutical industry today, it is questionable whether traditional, management will continue to prove an effective strategy, or whether they ultimately will be run over by smaller companies willing to bet on a larger vision, leanly executed.
In Asia, more than 120 people have been sickened, and 23 are dead, from a potent strain of bird flu that has the frightening markings of a potential pandemic strain. There’s a greater risk that this strain could acquire the ability to spread more easily from person to person. If it does, it could have devastating consequences.
Speculation is widespread about the potential origins of the Boston and U.S. Capitol attacks, and whether they could be related (seems unlikely). Investigations are underway. In time, we also must ask how much safer we’ve made ourselves based on the lessons we learned after 9-11. And whether there are still precautions we should heed.
As the controversy over climate policy has grown, it has been said that greenhouse gas (GHG) control is too hard but solar radiation management (SRM) is too easy. Join AEI for a discussion of the potential economic benefits, as well as the risks of SRM with Lee Lane, J. Eric Bickel and Nobel Laureate Thomas Schelling. A reception will follow.
At this event, panelists will address pension reform challenges by presenting the results of three research papers commissioned by AEI through a generous grant from the Smith Richardson Foundation.
Mark Warshawsky, a well-known expert in retirement finance and a newly appointed commissioner, will explain the implications of a publicly funded long-term care insurance program. Then a panel will debate whether another government program the best way to ensure that families can afford to provide the necessary services for their aging loved ones.